Literature DB >> 8640780

The paradoxical association of regression with a poor prognosis in melanoma contrasted with a good prognosis in keratoacanthoma.

R T Prehn1.   

Abstract

Partial regression in cutaneous malignant melanoma has been reported by a number of observers, albeit not all, to be associated with a relatively poor prognosis; in contrast, a keratoacanthoma, which eventually regresses, does not metastasize. The Hammond effect could explain the possibly poor prognosis of the thin regressing melanoma. Hammond(W.G. Hammond et al., Cancer J., 8: 130-138, 1995) showed that the speed of biological progression to less differentiated phenotypes is directly related to the immunocompetences of the tumor hosts. If partial regression is a sign of an unusually strong immune reaction, then the melanoma that partially regresses might have a relatively poor prognosis because of the greater risk of biological progression among the surviving tumor clones. A Hammond effect is not associated with regression of a keratoacanthoma. I postulate that the growth of this tumor is accelerated, rather than restrained, by the immune reaction and that the ultimate regression of the tumor is the result, not of immune cytotoxicity, but of a rapid terminal differentiation (a reverse Hammond effect); alternatively, very rapid growth might lead to an exhaustion of growth potential before progression to clonal immortality could occur.

Entities:  

Mesh:

Year:  1996        PMID: 8640780

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

1.  Mechanisms of regression.

Authors:  Dirk M Elston
Journal:  Clin Med Res       Date:  2004-05

2.  Association of microvessel density with infiltrating cells in human cutaneous malignant melanoma.

Authors:  Judit Kiss; József Tímár; Beáta Somlai; Katalin Gilde; Zsuzsanna Fejôs; István Gaudi; Andrea Ladányi
Journal:  Pathol Oncol Res       Date:  2007-03-27       Impact factor: 3.201

3.  [Regression in malignant melanoma. Definition, etiopathogenesis, morphology and differential diagnosis].

Authors:  B E Paredes
Journal:  Pathologe       Date:  2007-11       Impact factor: 1.011

Review 4.  Immunoglobulin expression in non-lymphoid lineage and neoplastic cells.

Authors:  Zhengshan Chen; Xiaoyan Qiu; Jiang Gu
Journal:  Am J Pathol       Date:  2009-02-26       Impact factor: 4.307

5.  Prognostic parameters for the primary care of melanoma patients: what is really risky in melanoma?

Authors:  Daniela Göppner; Martin Leverkus
Journal:  J Skin Cancer       Date:  2011-10-11

6.  Immunohistochemical staining for desmogleins 1 and 2 in keratinocytic neoplasms with squamous phenotype: actinic keratosis, keratoacanthoma and squamous cell carcinoma of the skin.

Authors:  A L Krunic; D R Garrod; S Madani; M D Buchanan; R E Clark
Journal:  Br J Cancer       Date:  1998-04       Impact factor: 7.640

7.  Keratoacanthomas have an immunosuppressive cytokine environment of increased IL-10 and decreased GM-CSF compared to squamous cell carcinomas.

Authors:  M A Lowes; G A Bishop; B E Cooke; R S Barnetson; G M Halliday
Journal:  Br J Cancer       Date:  1999-07       Impact factor: 7.640

Review 8.  Nanotechnology-Based Drug Delivery Systems for Melanoma Antitumoral Therapy: A Review.

Authors:  Roberta Balansin Rigon; Márcia Helena Oyafuso; Andressa Terumi Fujimura; Maíra Lima Gonçalez; Alice Haddad do Prado; Maria Palmira Daflon Gremião; Marlus Chorilli
Journal:  Biomed Res Int       Date:  2015-05-11       Impact factor: 3.411

9.  Tumor necrosis factor alpha-gene therapy for an established murine melanoma using RGD (Arg-Gly-Asp) fiber-mutant adenovirus vectors.

Authors:  Yuka Okada; Naoki Okada; Shinsaku Nakagawa; Hiroyuki Mizuguchi; Koichi Takahashi; Nobuyasu Mizuno; Takuya Fujita; Akira Yamamoto; Takao Hayakawa; Tadanori Mayumi
Journal:  Jpn J Cancer Res       Date:  2002-04

10.  Overexpression of immunoglobulin G prompts cell proliferation and inhibits cell apoptosis in human urothelial carcinoma.

Authors:  Pei-Yu Liang; Hao-Yong Li; Zhi-Yan Zhou; Ying-Xia Jin; Sheng-Xing Wang; Xiao-Hui Peng; Shan-Ji Ou
Journal:  Tumour Biol       Date:  2013-03-13
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.